ITCI
Income statement / Annual
Last year (2024), Intra-Cellular Therapies, Inc.'s total revenue was $680.85 M,
an increase of 46.62% from the previous year.
In 2024, Intra-Cellular Therapies, Inc.'s net income was -$74.68 M.
See Intra-Cellular Therapies, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$680.85 M |
$464.37 M |
$249.13 M |
$81.71 M |
$22.53 M |
$60.61 K |
$0.00 |
$245.84 K |
$330.70 K |
$91.36 K |
| Cost of Revenue |
$56.96 M
|
$33.75 M
|
$20.44 M
|
$8.03 M
|
$1.90 M
|
$477.12 K
|
$368.67 K
|
$79.42 M
|
$93.83 M
|
$139.63 K
|
| Gross Profit |
$623.89 M
|
$430.63 M
|
$228.69 M
|
$73.67 M
|
$20.64 M
|
-$416.51 K
|
-$368.67 K
|
-$79.17 M
|
-$93.50 M
|
-$48.26 K
|
| Gross Profit Ratio |
0.92
|
0.93
|
0.92
|
0.9
|
0.92
|
-6.87
|
0
|
-322.06
|
-282.73
|
-0.53
|
| Research and Development Expenses |
$236.12 M
|
$180.14 M
|
$134.72 M
|
$88.85 M
|
$65.78 M
|
$89.12 M
|
$132.17 M
|
$79.42 M
|
$93.83 M
|
$87.72 M
|
| General & Administrative Expenses |
$0.00
|
$317.66 M
|
$272.98 M
|
$190.11 M
|
$150.06 M
|
$64.95 M
|
$30.10 M
|
$23.67 M
|
$24.76 M
|
$18.19 M
|
| Selling & Marketing Expenses |
$0.00
|
$92.20 M
|
$85.80 M
|
$82.50 M
|
$36.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$504.49 M
|
$409.86 M
|
$358.78 M
|
$272.61 M
|
$186.36 M
|
$64.95 M
|
$30.10 M
|
$23.67 M
|
$24.76 M
|
$18.19 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$1.18 M
|
-$2.10 M
|
-$282.23 K
|
$0.00
|
$0.00
|
-$245.84 K
|
-$330.70 K
|
-$60.71 K
|
| Operating Expenses |
$740.61 M
|
$590.01 M
|
$492.32 M
|
$359.36 M
|
$251.86 M
|
$154.07 M
|
$162.27 M
|
$103.09 M
|
$118.59 M
|
$105.91 M
|
| Cost And Expenses |
$797.57 M
|
$623.75 M
|
$512.76 M
|
$367.40 M
|
$253.76 M
|
$154.07 M
|
$162.27 M
|
$103.09 M
|
$118.59 M
|
$105.91 M
|
| Interest Income |
$42.52 M
|
$20.34 M
|
$7.38 M
|
$1.57 M
|
$4.24 M
|
$6.29 M
|
$7.14 M
|
$4.01 M
|
$2.94 M
|
$1.02 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$36.78 K
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$528.00 K
|
$656.00 K
|
$533.36 K
|
$528.12 K
|
$477.12 K
|
$368.67 K
|
$213.87 K
|
$196.87 K
|
$139.63 K
|
| EBITDA |
-$116.72 M |
-$158.85 M |
-$262.97 M |
-$285.16 M |
-$230.70 M |
-$153.53 M |
-$161.90 M |
-$102.63 M |
-$115.13 M |
-$104.65 M |
| EBITDA Ratio |
-0.17
|
-0.34
|
-1.06
|
-3.49
|
-10.24
|
-2533.03
|
0
|
-417.46
|
-348.13
|
-1145.44
|
| Operating Income Ratio |
-0.17
|
-0.34
|
-1.06
|
-3.5
|
-10.26
|
-2540.9
|
0
|
-418.33
|
-357.6
|
-1158.16
|
| Total Other Income/Expenses Net |
$42.52 M
|
$20.34 M
|
$7.38 M
|
$1.57 M
|
$4.24 M
|
$6.29 M
|
$7.14 M
|
$4.01 M
|
$2.90 M
|
$1.02 M
|
| Income Before Tax |
-$74.20 M
|
-$139.04 M
|
-$256.25 M
|
-$284.12 M
|
-$226.99 M
|
-$147.72 M
|
-$155.13 M
|
-$98.83 M
|
-$115.36 M
|
-$104.79 M
|
| Income Before Tax Ratio |
-0.11
|
-0.3
|
-1.03
|
-3.48
|
-10.07
|
-2437.11
|
0
|
-402.03
|
-348.84
|
-1146.97
|
| Income Tax Expense |
$473.00 K
|
$636.00 K
|
$6.00 K
|
$5.63 K
|
$13.51 K
|
$1.60 K
|
$1.60 K
|
-$1.06 M
|
$1.07 M
|
$1.60 K
|
| Net Income |
-$74.68 M
|
-$139.67 M
|
-$256.26 M
|
-$284.13 M
|
-$227.01 M
|
-$147.72 M
|
-$155.13 M
|
-$97.77 M
|
-$116.43 M
|
-$104.79 M
|
| Net Income Ratio |
-0.11
|
-0.3
|
-1.03
|
-3.48
|
-10.08
|
-2437.14
|
0
|
-397.72
|
-352.06
|
-1146.99
|
| EPS |
-0.72 |
-1.46 |
-2.72 |
-3.5 |
-3.23 |
-2.68 |
-2.84 |
-2.12 |
-2.69 |
-2.91 |
| EPS Diluted |
-0.72 |
-1.46 |
-2.72 |
-3.5 |
-3.23 |
-2.68 |
-2.84 |
-2.12 |
-2.69 |
-2.91 |
| Weighted Average Shares Out |
$103.13 M
|
$95.88 M
|
$94.05 M
|
$81.25 M
|
$70.36 M
|
$55.19 M
|
$54.71 M
|
$46.18 M
|
$43.24 M
|
$36.01 M
|
| Weighted Average Shares Out Diluted |
$103.13 M
|
$95.88 M
|
$94.05 M
|
$81.25 M
|
$70.36 M
|
$55.19 M
|
$54.71 M
|
$46.18 M
|
$43.24 M
|
$36.07 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
